跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

E-068

Supelco

依维莫司 溶液

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C53H83NO14
CAS號碼:
159351-69-6
分子量：:
958.22
MDL號碼:
MFCD00929329
分類程式碼代碼:
41116107
PubChem物質ID:
329798983
NACRES:
NA.24
暫時無法取得訂價和供貨情況

等級

certified reference material

品質等級

300

形狀

liquid

特點

(Snap-N-Spike®)

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

濃度

1.0 mg/mL in acetonitrile

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

形式

single component solution

運輸包裝

dry ice

儲存溫度

−70°C

SMILES 字串

N21[C@@H](CCCC2)C(=O)O[C@@H](CC(=O)[C@@H](\C=C(\[C@H]([C@H](C(=O)[C@@H](C[C@@H](\C=C\C=C\C=C(\[C@H](C[C@H]4O[C@]([C@@H](CC4)C)(C(=O)C1=O)O)OC)/C)C)C)OC)O)/C)C)[C@@H](C[C@H]3C[C@H]([C@@H](CC3)OCCO)OC)C

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChI 密鑰

HKVAMNSJSFKALM-GKUWKFKPSA-N

基因資訊

human ... FKBP1A(2280)

相關類別

一般說明

以Zortress®、Certican和Afinitor®等商品名出售的依维莫司是一种免疫抑制剂，可用于防止器官移植排斥并治疗肾细胞癌和其他肿瘤。此认证加标溶液®适合用作从校准物、对照品或线性标准品的起始材料，通过LC/MS或GC/MS对患者全血样品中的依维莫司进行治疗性药物监测或临床和诊断检验。

法律資訊

Afinitor is a registered trademark of Novartis AG
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zortress is a registered trademark of Novartis AG

象形圖

FlameExclamation mark
GHS02,GHS07

訊號詞

Danger

危險分類

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

35.6 °F - closed cup

閃點（°C）

2.0 °C - closed cup

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助，請聯絡 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Ian T Meredith et al.
The American journal of cardiology, 113(7), 1117-1123 (2014-02-18)
In the randomized PLATINUM trial, the PROMUS Element platinum-chromium everolimus-eluting stent (PtCr-EES; Boston Scientific, Natick, Massachusetts) was noninferior to the XIENCE V cobalt-chromium everolimus-eluting stent (CoCr-EES; Boston Scientific and Abbott Vascular, Santa Clara, California) for the primary end point of
Catherine Lombard-Bohas et al.
Bulletin du cancer, 101(2), 175-183 (2014-02-22)
Medical management of pancreatic neuroendocrine tumors has recently been improved by new molecules of which the mTOR inhibitor everolimus. If digestive neuroendocrine tumors are rare, the incidence is in constant increase and the prevalence in digestive cancers put them right
L M Neri et al.
Leukemia, 28(4), 739-748 (2013-07-31)
B-precursor acute lymphoblastic leukemia (B-pre ALL) is a malignant disorder characterized by the abnormal proliferation of B-cell progenitors. The prognosis of B-pre ALL has improved in pediatric patients, but the outcome is much less successful in adults. Constitutive activation of
Michael Cardamone et al.
The Journal of pediatrics, 164(5), 1195-1200 (2014-02-13)
To evaluate the efficacy and side effects of oral mammalian target of rapamycin (mTOR) inhibitors in children and adolescents with tuberous sclerosis complex (TSC) and intractable epilepsy or subependymal giant cell astrocytoma (SEGA). Single-center series of 13 children and adolescents
Matteo Santoni et al.
Biochimica et biophysica acta, 1845(2), 221-231 (2014-02-01)
The mammalian target of rapamycin (mTOR) has emerged as an attractive cancer therapeutic target. Treatment of metastatic renal cell carcinoma (mRCC) has improved significantly with the advent of agents targeting the mTOR pathway, such as temsirolimus and everolimus. Unfortunately, a
查看所有相關論文

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務